DRTS News & Events

Alpha Tau announced the treatment with Alpha DaRT of the first glioblastoma patient in Israel, and the first ever outside of the United States, performed at Hadassah University Medical Center in Jerusalem. The procedure was carried out by a multidisciplinary team led by Prof. Yigal Shoshan, Professor of Neurosurgery at Hadassah University Medical Center. Using the company's brain applicator under real-time stereotactic neuro-navigation, Alpha DaRT sources were precisely delivered to the recurrent tumor through a single burr hole entry point into the brain. The procedure was completed safely and without unexpected complications.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Amplitech Group Inc (AMPG) 90.12% +3.72, Sleep Number (SNBR) 114.25% +2.32, Momentus (MNTS) 52.16% +1.96, Angion Biomedica Corp (ELTX) 26.32% +1.72, OPTU Stock (OPTU) 3.55% +0.72, Defiance 1.75x MSTR ETF (MSTX) 20.02% +0.71, Cardiff Oncology (CRDF) 50.29% +0.53, Sellas Life Sciences (SLS) 13.25% +0.46, Autobot Holdings (ARBE) 4.39% +0.43, and Alpha Tau Medical Ltd (DRTS) 9.02% +0.36.

Alpha Tau announced that the FDA has cleared the company to proceed with enrollment of the final seven patients in its U.S. REGAIN trial, following the FDA's review of a pre-specified interim safety report of the first three patients treated in the trial. The company intends to recommence patient recruitment immediately, on the back of tremendous clinical interest in continuing the trial.